Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Cytokinetics (CYTK) over the last 12 years, with Q4 2023 value amounting to $28.3 million.

  • Cytokinetics' Accumulated Depreciation & Amortization rose 6583.6% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 6583.6%. This contributed to the annual value of $28.3 million for FY2023, which is 6583.6% up from last year.
  • Cytokinetics' Accumulated Depreciation & Amortization amounted to $28.3 million in Q4 2023, which was up 6583.6% from $17.1 million recorded in Q4 2022.
  • In the past 5 years, Cytokinetics' Accumulated Depreciation & Amortization registered a high of $28.3 million during Q4 2023, and its lowest value of $16.2 million during Q4 2021.
  • Its 5-year average for Accumulated Depreciation & Amortization is $22.1 million, with a median of $24.2 million in 2019.
  • As far as peak fluctuations go, Cytokinetics' Accumulated Depreciation & Amortization plummeted by 3430.06% in 2021, and later skyrocketed by 6583.6% in 2023.
  • Over the past 5 years, Cytokinetics' Accumulated Depreciation & Amortization (Quarter) stood at $24.2 million in 2019, then rose by 1.84% to $24.6 million in 2020, then plummeted by 34.3% to $16.2 million in 2021, then increased by 5.59% to $17.1 million in 2022, then skyrocketed by 65.84% to $28.3 million in 2023.
  • Its Accumulated Depreciation & Amortization stands at $28.3 million for Q4 2023, versus $17.1 million for Q4 2022 and $16.2 million for Q4 2021.